NASDAQ:AR 31 December 2025

March 12, 2026, 6:55 AM EDT. Novo Nordisk (NYSE:NVO) shares have dropped 47% in the past year, closing recently at $38.83. The stock shows mixed short-term performance with a 0.9% gain over seven days but a 21.3% loss over 30 days. Despite this, the five-year return remains positive at 15%. Analysts note a changing market outlook for the pharmaceutical giant, affecting volatility. A discounted cash flow (DCF) model suggests the stock is undervalued by 63%, with an intrinsic value estimated at $105.10 per share versus the current price. The company's profitability and earnings-growth balance continue to influence investor sentiment and P/E (price-to-earnings) evaluations. This analysis highlights value opportunities amid recent market pullbacks.